EC Number | Protein Variants | Comment | Organism |
---|---|---|---|
4.1.1.11 | A128E | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | A128S | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | C17R | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | D116Y | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | E130G | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | F107L | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | H21N | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | H21Q | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | I115V | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | L131P | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | L136P | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | L136R | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | M117I | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | M117V | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | additional information | construction of a panD mutant strain, the panD mutant grows as well as the wild-type in infected mice. Mice infected with wild-type Mycobacterium tuberculosis are treated with pyrazinoic acid (POA), and POA-resistant colonies are confirmed for pyrazinamide (PZA) and POA resistance. Genome sequencing reveals that 82% and 18% of the strains contain missense mutations in panD and clpC1, respectively. Location of amino acid sequence polymorphisms in PanD of POA-resistant Mycobacterium tuberculosis strains isolated from POA-treated mice | Mycobacterium tuberculosis |
4.1.1.11 | N127K | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | V138A | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
4.1.1.11 | V138M | naturally occuring mutation after treatment with pyrazinoic acid | Mycobacterium tuberculosis |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
4.1.1.11 | Mycobacterium tuberculosis | - |
- |
- |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
4.1.1.11 | aspartate decarboxylase | - |
Mycobacterium tuberculosis |
4.1.1.11 | PanD | - |
Mycobacterium tuberculosis |
EC Number | General Information | Comment | Organism |
---|---|---|---|
4.1.1.11 | malfunction | an in vivo-selected pyrazinoic acid-resistant Mycobacterium tuberculosis strain harbors a missense mutation in the aspartate decarboxylase PanD. Mice infected with wild-type Mycobacterium tuberculosis are treated with pyrazinoic acid (POA), and POA-resistant colonies are confirmed for pyrazinamide (PZA) and POA resistance. Genome sequencing reveals that 82% and 18% of the strains contain missense mutations in panD and clpC1, respectively. POA/PZA resistance-conferring panD mutations are observed in POA-treated mice but not yet among clinical strains isolated from PZA-treated human patients | Mycobacterium tuberculosis |